This site is intended for healthcare professionals

Nefecon filed with EMA for primary IgA Nephropathy.-Calliditas Therapeutics

Read time: 1 mins
Last updated:1st Jun 2021
Published:30th May 2021
Calliditas Therapeutics has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Nefecon (budesonide), a novel oral formulation targeting down regulation of IgA1 for the treatment of primary IgA Nephropathy (IgAN).
Condition: IgA Nephropathy/Bergers disease
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest